Redx Pharma PLC (AIM:REDX) is presenting at the American Association for Cancer Research conference next month.
On April 12, the group will deliver preclinical data on one of its lead assets, RXC004, used in combination with other cancer therapies.
The porcupine inhibitor is currently in both phase I and phase II clinical trials - as a combination therapy with an antibody drug and used on its own to treat cancer patients.
For more information, click here